Analysts Set Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Target Price at $22.13

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $22.1250.

A number of research analysts have recently commented on the company. Morgan Stanley upped their target price on Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. HC Wainwright raised their price target on shares of Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Royal Bank Of Canada lifted their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Finally, Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th.

Compass Pathways Trading Down 5.6%

Shares of CMPS stock opened at $5.41 on Friday. The company has a market cap of $519.47 million, a PE ratio of -1.99 and a beta of 1.90. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The stock’s 50 day simple moving average is $6.85 and its two-hundred day simple moving average is $6.29. Compass Pathways has a 1 year low of $2.25 and a 1 year high of $8.90.

Institutional Trading of Compass Pathways

A number of hedge funds have recently added to or reduced their stakes in CMPS. Flax Pond Capital LLC purchased a new position in Compass Pathways during the 4th quarter valued at about $364,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways in the 4th quarter worth $47,000. Seven Fleet Capital Management LP bought a new position in Compass Pathways in the fourth quarter worth about $276,000. Corient Private Wealth LLC lifted its position in shares of Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after buying an additional 1,200 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Compass Pathways by 457.5% in the 4th quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock valued at $392,000 after buying an additional 46,600 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.